Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
- PMID: 24875380
- DOI: 10.2174/1389450115666140528151649
Non-Small Cell Lung Carcinoma: An Overview on Targeted Therapy
Abstract
Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease at cellular and molecular level however have helped researchers in devising novel strategies for therapy. These directed therapies limit cancer growth by targeting specific molecules related with tumor progression. Such strategies have shown to be more effective than chemotherapy and radiotherapy and can be complemented to existing therapeutic paradigm in augmenting beneficial outcome. Lung cancer could benefit from such innovative therapy. RNA interference (RNAi) is a sequence-specific gene silencing mechanism and, since its discovery widespread applications have pointed it as a powerful tool in cancer treatment. Several on-going clinical trials have been successfully demonstrating its potential as a novel therapeutic, including in the treatment of NSCLC. Here, we revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy for NSCLC treatment.
Similar articles
-
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613. J Cancer Res Ther. 2016. PMID: 28230005 Review.
-
Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.Oncotarget. 2015 Feb 20;6(5):3335-45. doi: 10.18632/oncotarget.2793. Oncotarget. 2015. PMID: 25595901 Free PMC article.
-
From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?Expert Rev Anticancer Ther. 2017 Feb;17(2):157-165. doi: 10.1080/14737140.2017.1273111. Epub 2017 Jan 5. Expert Rev Anticancer Ther. 2017. PMID: 27984919 Review.
-
Lung Cancer: Management.FP Essent. 2018 Jan;464:27-30. FP Essent. 2018. PMID: 29313655 Review.
-
[New therapeutic strategies and current research in inoperable locally advanced non small-cell lung cancers (stage IIIB)].Bull Cancer. 1997 Apr;84(4):413-9. Bull Cancer. 1997. PMID: 9238166 Review. French.
Cited by
-
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.Life (Basel). 2022 Oct 19;12(10):1640. doi: 10.3390/life12101640. Life (Basel). 2022. PMID: 36295075 Free PMC article. Review.
-
Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion.Cancer Cell Int. 2020 Jun 16;20:247. doi: 10.1186/s12935-020-01310-y. eCollection 2020. Cancer Cell Int. 2020. PMID: 32550825 Free PMC article.
-
The Emerging Role of EVA1A in Different Types of Cancers.Int J Mol Sci. 2022 Jun 15;23(12):6665. doi: 10.3390/ijms23126665. Int J Mol Sci. 2022. PMID: 35743108 Free PMC article. Review.
-
Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing.Front Genet. 2020 May 8;11:352. doi: 10.3389/fgene.2020.00352. eCollection 2020. Front Genet. 2020. PMID: 32457792 Free PMC article.
-
MiR-206 may suppress non-small lung cancer metastasis by targeting CORO1C.Cell Mol Biol Lett. 2020 Mar 17;25:22. doi: 10.1186/s11658-020-00216-x. eCollection 2020. Cell Mol Biol Lett. 2020. PMID: 32206066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical